One of the principal findings of our study was that the IL18-rs1834481 polymorphism appeared to have a strong impact on COVID-19 clinical outcome, since heterozygotes for the rs1834481 polymorphism were at a higher risk of developing pneumonia (both in univariate and multivariate analyses). This evidence concerns the gene IL18 and susceptibility to pneumonia measurement.